|
|
Dipyridamole: Tablet Formulation
Difficult to Analyze: Several Tertiary Amines
Method Conditions
| Column |
Cogent Bidentate C18™, 4µm, 100A |
| Catalog No. |
40018-75P |
| Dimensions |
4.6 x 75 mm |
| Mobile Phase |
A: 100% DI water 0.1% Phosphoric Acid
B: 80:20 Acetonitrile: 0.1% Phosphoric Acid |
| Gradient |
Time=0 0%B
Time=15 min 100% B (linear gradient) |
| Flow rate |
1.5 mL/min. |
| Peaks |
Main Peak: Dipyridamole
Minor Peaks: Tablet Excipients
|
| Injection Volume |
10 µL |
| Detection |
UV 280 nm |
| Temperature |
40°C |
Discussion
Easy to prepare this useful gradient separation of Dipyridamole of a USP tablet formulation. Note the excellent resolution from
capsule excipients, along with the excellent peak shape for this complex, difficult molecule.
|
Note: Dipyridamole is a drug that inhibits thrombus formation when given chronically and causes vasodilation when given at
high doses over short time. Modified release dipyridamole is used in conjunction with aspirin (under the trade names Aggrenox
in the USA or Asasantin Retard in the UK) in the secondary prevention of stroke and transient ischaemic attack. Dipyridamole
absorption is pH-dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor) will
inhibit uptake significantly.
|
|
